List of Excipients in Branded Drug RAPAMUNE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	RAPAMUNE	sirolimus	0008-1030	POLYSORBATE 80
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	RAPAMUNE	sirolimus	0008-1030	PROPYLENE GLYCOL

Rapamune Excipient Strategy and Commercial Opportunities for Sirolimus

Last updated: September 1, 2026

Rapamune is an oral sirolimus product with two distinct excipient platforms: a solvent-based oral solution and film-coated tablets. The solution depends on phospholipid-based solubilization, polysorbate 80, and ethanol. The tablets use a conventional solid dosage system built around lactose, sucrose, macrogol, talc, and titanium dioxide. The main commercial opportunities are generic substitution, alcohol-free liquid formulations, pediatric and dysphagia-friendly products, transplant adherence products, and differentiated sirolimus delivery systems for non-transplant indications.

Rapamune's original product and core composition patents have expired in the United States. Current barriers are primarily formulation development, bioequivalence, manufacturing control, immunosuppressant handling, supply reliability, and physician acceptance rather than basic compound exclusivity.

What is Rapamune and which excipients does it contain?

Rapamune is the brand name for sirolimus, an mTOR inhibitor approved by the FDA for prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. Wyeth Pharmaceuticals originally developed the product; Pfizer acquired Wyeth in 2009. Rapamune is marketed as tablets and as a 1 mg/mL oral solution.[1]

Rapamune dosage forms and inactive ingredients

Product	Strength	Primary excipient strategy	Key inactive ingredients reported in U.S. labeling
Rapamune oral solution	1 mg/mL	Lipid/phospholipid solubilization in a hydroalcoholic liquid	Phosal 50 PG, polysorbate 80, ethanol
Rapamune tablet	0.5 mg	Conventional compressed, film-coated solid dosage form	Lactose monohydrate, sucrose, macrogol, talc, titanium dioxide, colorants
Rapamune tablet	1 mg	Same core platform with strength-specific appearance	Lactose monohydrate, sucrose, macrogol, talc, titanium dioxide, colorants
Rapamune tablet	2 mg	Same core platform with strength-specific appearance	Lactose monohydrate, sucrose, macrogol, talc, titanium dioxide, colorants

The exact excipient composition and colorant profile should be taken from the product-specific FDA label and current DailyMed entry before regulatory or formulation decisions. The oral solution label identifies Phosal 50 PG, polysorbate 80, and ethanol as key inactive ingredients.[1,2]

Why the excipient system matters

Sirolimus is highly lipophilic and has poor aqueous solubility. Its absorption is variable and affected by food. The oral solution's excipient system addresses solubilization and dispersion rather than simple aqueous dilution. Phosal 50 PG provides a phospholipid-based vehicle, while polysorbate 80 supports wetting and dispersion. Ethanol contributes to solvent capacity.

The tablet platform reduces handling complexity and avoids the alcohol content of the oral solution. It also supports commercial advantages in storage, shipping, dosing convenience, and patient acceptance.

What excipient strategy does Rapamune use for the oral solution?

Rapamune's oral solution uses a lipid-based, self-dispersing formulation rather than a conventional water-based solution.

Phosal 50 PG as the principal solubilization vehicle

Phosal 50 PG is a proprietary phospholipid excipient system containing phosphatidylcholine, propylene glycol, and related lipid components. It is used to maintain sirolimus in a solubilized or finely dispersed state during dosing and gastrointestinal dilution.

This creates several formulation and commercial implications:

• The product depends on controlled raw-material composition.
• Phospholipid content can affect viscosity, dispersion, assay, and dissolution.
• The formulation requires close control of mixing order, temperature, and hold time.
• Compatibility with container closures and dosing devices must be demonstrated.
• Substitution with a different lipid excipient may require more than routine formulation optimization.

A generic developer can reproduce the listed excipient composition or pursue a different formulation route. The second option may create a regulatory and bioequivalence burden because sirolimus has a narrow therapeutic window and variable pharmacokinetics.

Polysorbate 80 and stability risk

Polysorbate 80 is widely used as a solubilizer and surfactant, but it can undergo oxidation and hydrolysis. Degradation may generate peroxides, free fatty acids, and subvisible particles. A sirolimus liquid product must therefore control:

• Peroxide burden in excipients.
• Oxygen exposure during manufacture and filling.
• Light exposure.
• Container-closure interaction.
• Microbial quality.
• Long-term assay and impurity stability.

A low-peroxide polysorbate supply and strong excipient incoming-control program can reduce development risk. The opportunity is relevant for suppliers offering pharmaceutical-grade polysorbate 80 with enhanced oxidation control, lot characterization, and documentation.

Ethanol creates a differentiation opportunity

The branded oral solution contains ethanol. That creates commercial space for an alcohol-free or low-alcohol sirolimus liquid, especially for:

• Pediatric transplant patients.
• Patients with alcohol restrictions.
• Long-term home use.
• Patients with swallowing difficulty.
• Institutional settings seeking simplified administration.
• Caregivers concerned about flammability and storage.

An alcohol-free product would need to preserve solubility, dose uniformity, microbial stability, palatability, and bioequivalence. Candidate platforms include self-emulsifying drug delivery systems, mixed micelles, cosolvent systems, amorphous dispersions, and nanosuspensions.

What formulations are protected by Rapamune patents?

Rapamune's original U.S. compound and product exclusivity has expired. Sirolimus is not a biologic, so biosimilar pathways do not apply. FDA approval of generic sirolimus is pursued through the abbreviated new drug application pathway.

Core patent position

The original sirolimus patent estate included patents covering the active compound and pharmaceutical use. Key early U.S. patents associated with sirolimus include U.S. Patent No. 5,100,899 and related patents. The principal compound patent term expired years ago, subject to applicable patent-term adjustments and extensions.[3]

The commercial importance of those patents is historical. They do not create a current compound-level barrier to generic sirolimus tablets or oral liquids.

Formulation and method-of-use rights

Potentially relevant rights historically included:

• Oral formulations containing sirolimus.
• Dosing regimens for transplant immunosuppression.
• Combination use with calcineurin inhibitors or corticosteroids.
• Use in specific transplant populations.
• Formulation systems improving solubility or administration.

A formulation patent can remain relevant after compound patent expiry if it claims a genuinely distinct composition, process, or delivery system. For current U.S. launch planning, the relevant source is the FDA Orange Book listing for the reference product, together with the Patent and Exclusivity Data section and the public patent docket.[4]

Orange Book status and Paragraph IV risk

Rapamune is a small-molecule reference product. Generic applicants can submit Paragraph IV certifications against listed patents. A Paragraph IV certification can trigger patent litigation if the reference-product sponsor files suit within the statutory period.

The major risk categories are:

Risk area	Relevance to Rapamune
Compound patent	Low, because the original compound exclusivity expired
Tablet formulation	Potentially relevant if a listed formulation patent remains active
Oral solution composition	Potentially relevant where claims cover a specific lipid or surfactant system
Method of use	May affect labeled indications or carve-out strategy
Manufacturing process	Usually more relevant to trade-secret risk than ANDA blocking
Regulatory exclusivity	No current compound-level exclusivity expected from the original approval

A generic applicant can often design around a formulation patent by using different excipients, concentrations, manufacturing steps, or dosage-form architecture. That is the central commercial value of excipient innovation in this market.

When did Rapamune lose exclusivity?

Rapamune lost its principal U.S. compound exclusivity after expiry of the original sirolimus patent estate. FDA-approved generic sirolimus tablets are now available, and the reference product no longer has an effective monopoly over oral sirolimus supply.

Exclusivity timeline

Event	Approximate timing	Commercial effect
Sirolimus developed and approved for renal-transplant rejection prophylaxis	1999	Originator market established
Wyeth acquired by Pfizer	2009	Rapamune transferred into Pfizer's portfolio
Core compound patent expiry	Early-to-mid 2010s	Compound-level generic entry became possible
Generic sirolimus tablet approvals	Late 2010s onward	Tablet price and share pressure increased
Current market	2020s	Brand differentiation depends on supply, presentation, adherence, and clinical familiarity

Exact patent expiration dates should be assessed patent by patent because patent-term adjustment, patent-term extension, terminal disclaimers, and listed-patent status can alter the effective date. The original sirolimus patent family does not support a current broad exclusivity position comparable to a recently launched specialty drug.

Which companies are challenging or competing with Rapamune?

Competition comes from generic sirolimus suppliers rather than biosimilar developers. Public U.S. drug databases and FDA product records identify generic sirolimus tablet products from sponsors including Dr. Reddy's Laboratories and Zydus Pharmaceuticals, among other approved or distributed suppliers.[4,5]

Competitive structure

Competitor type	Examples	Competitive basis
Brand reference product	Rapamune, Pfizer	Physician familiarity, reference status, established labeling
Generic tablets	Multiple ANDA sponsors	Price, wholesaler access, formulary placement
Generic oral solution	Limited relative to tablets	Presentation availability, manufacturing complexity
Compounded products	Pharmacy-specific	Patient-specific dosing, variable availability
Alternative immunosuppressants	Tacrolimus, cyclosporine, everolimus, mycophenolate	Clinical regimen, toxicity profile, physician preference

The tablet market is more accessible than the oral-solution market. Liquid development requires greater control of solubilization, physical stability, microbial protection, packaging, and dose measurement.

What are the commercial opportunities for Rapamune excipients?

The strongest opportunities are differentiated formulations that solve a specific use problem without creating an unacceptable bioequivalence burden.

1. Alcohol-free oral liquid

An alcohol-free liquid could target pediatric transplant care, dysphagia, home administration, and institutional use. The formulation must maintain sirolimus solubility after dilution and throughout shelf life.

Potential excipient platforms include:

• Phospholipid-based self-emulsifying systems.
• Medium-chain triglyceride and surfactant systems.
• Cyclodextrin complexes.
• Nanocrystal suspensions.
• Amorphous polymer dispersions.
• Low-ethanol or ethanol-free cosolvent systems.

The commercial value is highest if the product provides a meaningful administration advantage while remaining substitutable or clinically acceptable.

2. Taste-masked pediatric liquid

Sirolimus has a bitter taste. A pediatric product could combine a solubilizing vehicle with sweeteners, flavors, and taste-masking polymers. The key issue is avoiding excipients that destabilize the lipid system or alter absorption.

A successful product would need:

• Dose uniformity at small volumes.
• Acceptable taste after repeated administration.
• Compatibility with oral syringes.
• Stable dosing after shaking.
• Clear instructions for dilution and administration.
• Low microbial risk without excessive preservative load.

3. Ready-to-use unit-dose presentations

Unit-dose cups, prefilled oral syringes, or single-use sachets could reduce preparation errors and caregiver burden. These presentations may be valuable even without a new active ingredient.

The main development issues are extractables and leachables, oxygen ingress, sorption of sirolimus to plastics, and dose recovery from the delivery device.

4. Improved solid dosage forms

Tablet-focused innovation can target:

• Smaller tablets.
• Orally disintegrating tablets.
• Sprinkle formulations.
• Mini-tablets for pediatric use.
• Flexible strengths to reduce tablet splitting.
• High-content tablets that reduce pill burden.
• Blister packaging with moisture and light protection.

Because sirolimus exposure is clinically important, any change in disintegration, dissolution, particle size, or excipient composition requires careful pharmacokinetic evaluation.

5. Long-acting sirolimus delivery

Long-acting implants, depot injections, and controlled-release systems are technically attractive but commercially more difficult. Sirolimus has immunosuppressive activity, and uncontrolled exposure could create serious safety concerns.

Potential platforms include biodegradable microspheres, implants, drug-eluting devices, and localized delivery for non-transplant indications. These products would likely require a new drug application or a substantial clinical development program rather than a conventional generic pathway.

How strong is the Rapamune patent estate?

The current patent estate is moderate to weak for conventional oral generic competition and stronger for genuinely differentiated delivery systems.

Patent category	Current strength
Sirolimus molecule	Weak because core patents have expired
Conventional tablet	Weak to moderate, depending on active listed claims
Branded oral solution composition	Moderate where claims cover proprietary lipid architecture
Alcohol-free liquid	Potentially strong if supported by novel composition claims
Pediatric delivery device	Potentially strong if claims cover device and formulation combination
Long-acting delivery	Potentially strong, but dependent on new clinical and formulation data
Manufacturing process	Moderate as confidential know-how; weaker if independently reproducible

Excipient selection can support patentability when it creates a non-obvious composition with measurable technical advantages, such as improved stability, reduced ethanol, lower food effect, better dose recovery, or enhanced bioavailability. Merely replacing one conventional excipient with another is less likely to create durable patent protection.

What manufacturing and IP barriers affect sirolimus excipient products?

The principal manufacturing barriers are technical rather than legal.

Critical manufacturing controls

Liquid products require control of:

• Excipient identity and composition.
• Mixing energy and sequence.
• Temperature exposure.
• Oxygen and light exposure.
• Homogeneity during filling.
• Container-closure compatibility.
• Microbial limits and preservative performance.
• Assay and degradation products.

Solid products require control of:

• Sirolimus particle size.
• Blend uniformity at low drug loading.
• Granulation and compression behavior.
• Dissolution across pH conditions.
• Film-coating uniformity.
• Moisture protection.
• Content uniformity between strengths.

Trade secrets can provide meaningful protection in these areas. Examples include order of addition, temperature windows, pre-dispersion methods, lipid preconditioning, deaeration, and filling controls. These methods may be difficult to reverse-engineer from the finished product.

What is the FDA regulatory status of Rapamune and its generics?

Rapamune is FDA-approved as an oral sirolimus product for renal-transplant rejection prophylaxis in patients at least 13 years old. Generic sirolimus products are approved through ANDAs demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug.[1,4]

There is no biosimilar pathway for Rapamune because sirolimus is a chemically synthesized small molecule, not a biologic. A new excipient or materially different delivery system may require an NDA, a 505(b)(2) application, or an ANDA only if the product remains within the applicable sameness and bioequivalence framework.

The FDA Inactive Ingredient Database can help assess whether a proposed excipient and route have prior precedent. It does not eliminate the need to justify concentration, formulation function, safety, and product-specific performance.[6]

How does Rapamune compare with everolimus?

Rapamune and everolimus are both mTOR inhibitors, but they occupy different formulation and commercial positions.

Attribute	Rapamune	Everolimus
Active ingredient	Sirolimus	Everolimus
Drug class	mTOR inhibitor	mTOR inhibitor
Transplant use	Renal transplantation	Multiple transplant and oncology uses, depending on product
Main oral forms	Tablets and oral solution	Tablets and dispersible tablets for selected products
Excipient opportunity	Alcohol-free liquid, lipid delivery, pediatric administration	Dispersible and indication-specific presentations
Generic risk	Established generic competition	Also exposed to generic competition in mature indications
Biosimilar risk	None	None for chemically synthesized everolimus

Rapamune's liquid presentation creates a more visible excipient opportunity than a tablet-only product. Everolimus may offer broader indication diversification, while sirolimus offers a clearer niche in transplant liquid delivery and adherence-focused formulations.

What revenue exposure does Rapamune face from generic entry?

Rapamune's revenue exposure is concentrated in the transplant market, where generic substitution can reduce unit price and shift volume away from the brand. Pfizer reports many products within broader commercial categories and does not consistently disclose Rapamune revenue as a standalone line item in public financial reporting.[7]

Commercial pressure is greatest for standard tablets because:

• Multiple generic suppliers can compete.
• Tablet manufacturing is comparatively conventional.
• Payers can substitute based on formulary rules.
• The active ingredient is well characterized.
• Core patent protection has expired.

The oral solution can retain a narrower commercial position because fewer suppliers may pursue it. A differentiated liquid can command value if it improves dosing, tolerability, or administration without requiring a major change in clinical practice.

What generic launch scenarios exist for Rapamune?

Scenario 1: Standard tablet substitution

This is the lowest-risk pathway. A sponsor launches 0.5 mg, 1 mg, and 2 mg tablets using conventional excipients and competes primarily on price and supply.

Scenario 2: Generic oral solution

This pathway is more technically demanding. The sponsor must reproduce clinically acceptable exposure while managing lipid excipient variability, ethanol, packaging, and stability.

Scenario 3: Alcohol-free liquid

This is a differentiated opportunity. The sponsor may obtain stronger commercial positioning but could face a more complex regulatory route if the formulation departs materially from the reference product.

Scenario 4: Pediatric mini-tablet or dispersible product

This product could address dose flexibility and swallowing problems. The commercial opportunity is smaller than the adult tablet market but may support durable formulation claims and institutional contracts.

Scenario 5: New delivery system

A depot, implant, or localized sirolimus product could create substantial new IP. It would also require clinical evidence and would not be a routine generic substitution product.

Key Takeaways

• Rapamune is sirolimus, an oral mTOR inhibitor for renal-transplant immunosuppression.
• Its oral solution uses Phosal 50 PG, polysorbate 80, and ethanol to address sirolimus solubility.
• Its tablets use a conventional lactose- and sucrose-containing film-coated platform.
• Core sirolimus patent protection has expired, and generic tablets are established.
• The strongest excipient opportunities are alcohol-free liquids, pediatric formulations, taste masking, unit-dose packaging, and improved dose delivery.
• The oral solution is a more attractive formulation target than standard tablets because lipid solubilization and packaging create technical barriers.
• Rapamune has no biosimilar risk because sirolimus is a small molecule.
• Current commercial protection depends more on formulation performance, manufacturing know-how, supply reliability, and patient administration benefits than on compound patents.

FAQs

Can Phosal 50 PG be replaced in a generic sirolimus oral solution?

Yes, but replacement may materially change solubilization, dispersion, absorption, stability, and bioequivalence. A substitute system would require product-specific development and regulatory justification.

Is ethanol-free sirolimus commercially viable?

Yes. An ethanol-free liquid could target pediatric, dysphagia, home-care, and institutional use. The principal technical challenge is maintaining solubility and exposure without the solvent contribution of ethanol.

Are sirolimus excipients eligible for composition-of-matter patent protection?

The excipient itself is usually not patentable as a new composition if it is known. A novel sirolimus formulation containing a defined excipient system may be patentable if it provides unexpected technical performance.

Does Rapamune have biosimilar competition?

No. Sirolimus is a chemically synthesized small molecule. Competition proceeds through generic drug applications rather than biosimilar applications.

Which Rapamune presentation has the greatest commercial opportunity?

The greatest differentiated opportunity is an alcohol-free, stable, palatable oral liquid with reliable dose recovery and pediatric usability. Standard tablets have greater volume but substantially lower differentiation potential.

References

1. U.S. Food and Drug Administration. (2023). Rapamune (sirolimus) prescribing information. Pfizer Laboratories.

2. National Library of Medicine. (2024). DailyMed: Rapamune sirolimus tablet and oral solution labeling. U.S. National Library of Medicine.

3. U.S. Patent and Trademark Office. (1992). U.S. Patent No. 5,100,899: Novel macrolides. U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. Center for Drug Evaluation and Research.

5. National Library of Medicine. (2024). DailyMed: Sirolimus tablet product listings. U.S. National Library of Medicine.

6. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.

7. Pfizer Inc. (2024). Annual report and Form 10-K. Pfizer Inc.